NeuroPace, Inc. (Nasdaq: NPCE) announced that its AI‑enabled clinician tool, ECoG Assistant™, has received U.S. Food and Drug Administration (FDA) approval. The feature adds automated analysis to the company’s responsive neurostimulation (RNS®) System, aiming to speed clinicians’ review of long‑term intracranial EEG (iEEG) recordings. The approval marks the first AI‑driven addition to NeuroPace’s platform and is positioned as a step toward a broader suite of AI tools for epilepsy care.
NeuroPace Announces FDA Approval of ECoG Assistant™
The FDA cleared ECoG Assistant as a clinician‑enabled feature that identifies “ECoGs of Interest” within the RNS System’s iEEG data. The model was trained on 124,450 epileptologist‑labeled long‑episode iEEG records, allowing it to flag relevant segments across months of monitoring. Physicians can view these segments in a single “Trends Report” and explore timing patterns with a “Circadian Pattern Chart.” Dr. Martha Morrell, Chief Medical Officer, said the tool “represents an important advancement in how clinicians interact with iEEG data and the RNS System.” CEO Joel Becker highlighted the company’s “data advantage” and noted that the AI‑driven insights are intended to make epilepsy care more efficient while laying groundwork for future personalization.
ECoG Assistant Features and Data Foundations
ECoG Assistant is the first component of a planned NeuroPace AI suite that will provide deeper data insights and streamline ECoG review. Built on the RNS System’s long‑term intracranial EEG dataset—the world’s only such dataset of its kind—the feature leverages patient‑level brain data collected over years of therapy. The AI model’s training set of over 124,000 labeled episodes is described as a “subset of the largest intracranial EEG dataset in the world.” By presenting flagged recordings and trend visualizations in a consolidated view, the tool aims to reduce the time clinicians spend manually scanning raw iEEG streams.
NeuroPace plans to demonstrate ECoG Assistant at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Annual Meeting on May 30, 2026, where clinicians will be able to interact with the technology directly.
Next‑Generation PDMS Submission and Timeline
Alongside the ECoG Assistant clearance, NeuroPace has submitted its next‑generation Patient Data Management System (PDMS) for FDA review. The cloud‑based PDMS is intended to modernize the software infrastructure that underpins the RNS System, improving reliability, scalability, and flexibility for future AI‑enabled capabilities. If approved, the company expects the PDMS to be cleared in the second quarter of 2026. Approval of the PDMS would provide a foundation for additional workflow tools, including the newly approved ECoG Assistant and other planned AI applications.
Key Takeaways
- The FDA cleared NeuroPace’s ECoG Assistant, the first AI‑driven clinician feature for the RNS System.
- The AI model was trained on 124,450 epileptologist‑labeled iEEG long‑episode records to identify “ECoGs of Interest.”
- NeuroPace expects its next‑generation Patient Data Management System to receive FDA approval in Q2 2026, creating a cloud‑based platform for further AI tools.
TechInsyte's Take
The clearance gives epilepsy specialists a new, data‑rich view of long‑term iEEG recordings, potentially reducing manual review effort. However, the practical impact on clinical workflow will depend on integration with existing hospital systems and the speed of PDMS approval. CIOs and health‑IT leaders should monitor the PDMS timeline and assess how the cloud‑based architecture aligns with their security and compliance frameworks before planning broader adoption.
Source: Businesswire
